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Assessing Value in Health Care Programs
Abstract
Many health care services provided in the United States are of low value, meaning that the cost of providing
those services is high relative to the health care benefit they confer. In some cases, the care provided may have
no value or even, on average, may be harmful. Examples of low- or negative-value services include unnecessary
surgery or diagnostic imaging that will not change management. Given estimates that 30% of the $2.5 trillion
the United States spends on health care services each year may provide little benefit,1 there is a widespread
eagerness to enhance the ratio of benefits to costs.
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VIEWPOINT
Assessing Value in Health Care Programs
Kevin G. Volpp, MD, PhD
George Loewenstein, PhD
David A. Asch, MD, MBA
MANY HEALTH CARE SERVICES PROVIDED IN THEUnited States are of low value, meaning thatthe cost of providing those services is high rela-tive to the health care benefit they confer. In
some cases, the care provided may have no value or even,
on average, may be harmful. Examples of low- or negative-
value services include unnecessary surgery or diagnostic
imaging that will not change management. Given esti-
mates that 30% of the $2.5 trillion the United States spends
on health care services each year may provide little ben-
efit,1 there is a widespread eagerness to enhance the ratio
of benefits to costs.
Because value matters in health care, when new health
care programs are proposed it has become common to ask,
“What is the return on investment from implementing this
new program?” Implicit in this question is that programs
should be supported if they save money but not otherwise.
Positive return on investment, meaning that more money
is saved than is spent, has become the standard by which
new initiatives are evaluated. This standard has been used
to evaluate new programs such as the primary care medical
home, disease management, and the projects submitted for
the new Center for Medicare & Medicaid Services Innova-
tion Challenge.
Although asking about return on investment might seem
to make sense given concerns about health care cost and
value, asking about return on investment is the wrong ques-
tion when assessing whether a health care program is suc-
cessful. What would happen if the rule were applied to ev-
ery health care decision that is made? Besides childhood
vaccination and flu shots for the elderly, few health care ser-
vices save money.2 The positive return-on-investment cri-
terion is not applied to most health care services because
almost nothing satisfies it. Medicare is prohibited by law from
considering cost in coverage decisions, and other insurers
tend to follow suit, even if the benefits are small and the
costs very large. Would anyone ever ask, “What is the re-
turn on investment in treatment of this patient’s cancer?”
This is not a meaningless question, but almost certainly one
that most people would think inappropriate to ask.
Cost is important and should be considered in many more
settings for both existing and new services. Clinicians and
policy makers should not apply one standard when tacitly
continuing the status quo and a different standard when
evaluating innovative programs that might be imple-
mented. It certainly does not make sense to use one crite-
rion—Are there clinical benefits?—for coverage decisions
for treatments and a different criterion—Are health care sav-
ings greater than program costs?—for preventive services
or for delivery system innovations designed to improve
health. Programs designed to improve health and prevent
disease should be evaluated based on whether they im-
prove health at a reasonable price, essentially comparing
whether improvements in health are achieved for less re-
sources than through alternatives, eg, expenditures on health
care services.
Health care reimbursement tends to be disease fixated and
should be evaluated the same way based on the value of ex-
penditures in achieving improvements in health.3 If an em-
ployer spends $100 000 treating late-stage emphysema or
lung cancer for its employees—an expenditure with a nega-
tive return on investment but one that adds value to em-
ployees’ lives—should that employer be willing to spend
money on smoking cessation programs? The answer is al-
most undoubtedly yes. However, if health promotion pro-
grams or health system delivery innovations are required
to save money, they will likely be labeled failures even if
they improve health at a lower price than many of the ser-
vices that we now willingly pay for under Medicare and pri-
vate insurance. If we continue with the approach of insist-
ing on a positive return on investment to fund such programs,
low-value spending will persist at higher rates than would
otherwise be the case.
For example, consider a program that would improve
medication adherence after acute myocardial infarction
(AMI). Adherence rates to -blockers, statins, angiotensin-
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converting enzyme inhibitors or angiotensin-receptor
blockers after an AMI event is poor; a recent large-scale
study showed that even when copayments were lowered to
$0 among insured patients, average adherence for these
medications was only about 45%.4 If a new program could
increase adherence to 70%, it is plausible that the program
could significantly reduce the rate of hospital admissions
for MI, stroke, and revascularization procedures. If the
average cost of health events requiring hospitalization in
the 12 months following a hospital admission for a new MI
is about $20 000 and the new program reduced the rate of
events requiring hospitalization by 10%, the new program
could cost up to $2000 per year and still save money. Does
that mean the program should not be adopted if it costs
$3000? At that point, the calculated return on investment
for the program is negative because it costs more than it
saves. But wouldn’t this program still be a much better use
of money than letting those MIs occur (mortality rates
from AMI are typically more than 10% among hospitalized
patients in the 30 days after admission, and many patients
die before making it to a hospital)? If this is deemed not a
good use of resources, then why are so many other ser-
vices covered that yield lower value?5 Many insurers,
including Medicare, are continuing to cover bevacizumab
for metastatic breast cancer, despite the unanimous recom-
mendation by a US Food and Drug Administration panel
that it not be covered because it is not helping patients to
live longer, does not control their tumors, and exposes
them to serious adverse effects6 and despite an average
annual cost of $99 000.7
There are political, ethical, and emotional challenges to
making explicit resource allocation issues in treating dis-
eases and applying the same metrics used to evaluate the
effectiveness of programs that prevent diseases in largely
unidentified patients. It is always more difficult to shut
down existing programs than to say no to new ones, a
phenomenon related to inertia, also known as status quo
bias.8 It is also more difficult to justify investments in
prevention across broad populations than investments in
the treatment of identifiable patients, a phenomenon
known as the rule of rescue.9 Changing the criteria used
to evaluate health system delivery innovations might help
overcome these tendencies. Evaluating success using the
same criteria—whether a preventive service, delivery sys-
tem innovation, or treatment—may be the best way to
ensure the maximal value in terms of improvements in
health for the resources expended on health care services.
A recent conversation with a benefits manager from a me-
dium-sized employer brought this point home. She re-
ported that when asked by the chief financial officer, “What
is the return on investment in putting in place this $125 000
wellness program?” she responded, “What is the return on
investment on the $28 million we are spending on treating
disease through our health benefits?” If cost is not consid-
ered when thinking about the value of covered treatments,
it does not make sense to use positive return on invest-
ment as a criterion for determining whether promising new
delivery system innovations should be covered. A better ap-
proach would be to adopt similar metrics for treatment and
prevention for current and proposed care, for which the goal
in all cases is achieving the most improvement possible with
the resources available.
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